EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Performance of the HPV E6 / E7 mRNA Aptima HPV assay combined with partial genotyping compared with the HPV DNA Cobas 4800 HPV test for use in primary screening: Results from the CERVIVA HPV primary screening study in Ireland

Christine White iD, Stephen Reynolds, Katherine Murphy, Helen Keegan, Padma Naik, Roisin O'Brien, Loretto Pilkington, Imogen Sharkey Ochoa, Grainne Glesson, Noirin Russell, David Nuttall, Prerna Tewari und 7 weitere

International Journal of Cancer · 2024-01 · 154 (1) · 53-64

DOI: 10.1002/ijc.34685 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Cancer, online erschienen am 26.08.2023. Verfasst von Christine White und 18 weiteren Autor:innen. Beteiligte Einrichtung: TCD CERVIVA Molecular Pathology Laboratory, Trinity College Dublin, Dublin, Ireland. Hauptthemen laut MEDLINE: Uterine Cervical Dysplasia, Uterine Cervical Neoplasms, Papillomavirus Infections. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Health Research Board.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

There are currently several validated HPV tests. However, longitudinal data which spans appropriate age ranges, as well as evaluation of potential screening algorithms are necessary for screening programmes choice of test. The objective of our study was to evaluate the performance of HPV mRNA and HPV DNA testing, including partial genotyping, in routine cervical screening. As part of the CERVIVA HPV Primary Screening Study, ThinPrep samples from 10 150 women were tested for HPV mRNA using the Aptima HPV assay and HPV DNA using the Cobas 4800 HPV test. HPV mRNA‐positive women were further assessed with the Aptima genotyping assay for HPV 16/18/45. Baseline cytology and prospective follow‐up data were collected. The performance of the two tests was examined over 42 months (to date). HPV mRNA demonstrated equivalent sensitivity to HPV DNA testing for detection of CIN2+ (93.2% [92.4‐93.9] vs 92.8% [92.0‐93.6], respectively) and CIN3+ (94.6% [93.8‐95.3] vs 94.6% [93.8‐95.3]). HPV mRNA testing had significantly higher specificity compared to HPV DNA for detection of CIN2+ (84.0% [83.5‐84.5] vs 80.8% [80.2‐81.4], respectively) and CIN3+ (88.44% [88.2‐88.6] vs 85.62 [85.4‐85.9]). The proportion of CIN2+ and CIN3+, over 3 years (42 months), in HPV‐negative women was comparable for both RNA (0.20% and 0.10%) and DNA (0.22% and 0.11%). Genotyping data was comparable across both assay platforms. In the context of HPV primary screening HPV mRNA testing has potential to reduce triage tests and follow‐up tests at 12 months compared to DNA testing, with no significant difference in detection of CIN2+ and CIN3+.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Uterine Cervical DysplasiaUterine Cervical NeoplasmsPapillomavirus InfectionsFemaleHumansEarly Detection of CancerRNA, MessengerGenotypeIrelandHuman papillomavirus 16Prospective StudiesHuman papillomavirus 18DNAPapillomaviridaeSensitivity and SpecificityDNA, Viral

Stichwörter der Autor:innen

HPV DNAHPV mRNAgenotypingscreening

Substanzen

RNA, MessengerDNADNA, Viral

Autor:innen und Institutionen

  • TCD CERVIVA Molecular Pathology Laboratory, Trinity College Dublin, Dublin, Ireland.
  • Discipline of Histopathology, St. James' University Hospital, Trinity College Dublin, Dublin, Ireland.
  • The Coombe Hospital, Dublin 8, Ireland.
  • CervicalCheck, National Screening Service, Kings Inns House, Dublin 1, Ireland.
  • Trinity St James Cancer Institute, Trinity College Dublin, Dublin, Ireland.
  • Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, UK.

ORCID-Profile: Christine White

Förderung

  • Health Research Board

Zitieren

APA

White, C., Reynolds, S., Murphy, K., Keegan, H., Naik, P., O'Brien, R., Pilkington, L., Sharkey Ochoa, I., Glesson, G., Russell, N., Nuttall, D., Tewari, P., Wright, F., O'Toole, S., Sharp, L., Flannelly, G., O'Leary, J. J., Martin, C. M., & CERVIVA the Irish Cervical Screening Research Consortium (2024). Performance of the HPV E6 / E7 mRNA Aptima HPV assay combined with partial genotyping compared with the HPV DNA Cobas 4800 HPV test for use in primary screening: Results from the CERVIVA HPV primary screening study in Ireland. International Journal of Cancer, 154(1), 53-64. https://doi.org/10.1002/ijc.34685

Vancouver

White C, Reynolds S, Murphy K, Keegan H, Naik P, O'Brien R, et al. Performance of the HPV E6 / E7 mRNA Aptima HPV assay combined with partial genotyping compared with the HPV DNA Cobas 4800 HPV test for use in primary screening: Results from the CERVIVA HPV primary screening study in Ireland. International Journal of Cancer. 2024;154(1):53-64. doi:10.1002/ijc.34685

BibTeX
@article{White2024,
  author = {White, Christine and Reynolds, Stephen and Murphy, Katherine and Keegan, Helen and Naik, Padma and O'Brien, Roisin and Pilkington, Loretto and Sharkey Ochoa, Imogen and Glesson, Grainne and Russell, Noirin and Nuttall, David and Tewari, Prerna and Wright, Fiona and O'Toole, Sharon and Sharp, Linda and Flannelly, Grainne and O'Leary, John J and Martin, Cara M and CERVIVA the Irish Cervical Screening Research Consortium, CERVIVA the Irish Cervical Screening Research Consortium},
  title = {Performance of the HPV E6 / E7 mRNA Aptima HPV assay combined with partial genotyping compared with the HPV DNA Cobas 4800 HPV test for use in primary screening: Results from the CERVIVA HPV primary screening study in Ireland},
  journal = {International Journal of Cancer},
  year = {2024},
  volume = {154},
  number = {1},
  pages = {53--64},
  doi = {10.1002/ijc.34685}
}
Kostenlos starten →